Related Experiment Video
Updated: Jun 10, 2026
04:22
Biomarker Identification for Gender Specificity of Alzheimer's Disease Based on the Glial Transcriptome Profiles
Published on: May 20, 2024
[Biological marker for Alzheimer's disease]
1Department of Neurology, Hirosaki University Graduate School of Medicine, Hirosaki, Aomori, Japan.
Brain and Nerve = Shinkei Kenkyu No Shinpo
|August 3, 2010
Summary
Developing Alzheimer disease (AD) treatments necessitates early diagnosis. This review focuses on amyloid beta-protein (Abeta) and tau biomarkers for accurate, early AD detection to guide treatment initiation.
Area of Science:
- Neuroscience
- Biochemistry
- Immunology
Context:
- Alzheimer disease (AD) modifying treatments are emerging.
- Early and accurate diagnosis is crucial for effective treatment initiation.
- Biomarkers are essential for early AD detection.
Purpose:
- To review recent advancements in identifying Alzheimer disease biomarkers.
- To highlight the role of amyloid beta-protein (Abeta) and tau in AD diagnosis.
- To underscore the importance of biomarkers for timely therapeutic intervention.
Summary:
- This review examines progress in identifying biological markers for Alzheimer disease.
- A particular focus is placed on amyloid beta-protein (Abeta) and tau.
- These biomarkers are key for early and accurate AD diagnosis.
Impact:
- Facilitates the development and application of early-stage AD treatments.
- Enables timely intervention, potentially slowing disease progression.
- Supports the clinical translation of novel AD diagnostic tools.
Related Concept Videos
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...